Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

NCT01266031 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

96

Enrollment

NIH

Sponsor class

Conditions

Malignant Glioma
Recurrent Glioblastoma

Interventions

DRUG: vorinostat
DRUG: bevacizumab

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]